<DOC>
	<DOCNO>NCT01074307</DOCNO>
	<brief_summary>This prospective , open-labeled , multi-centric trial evaluate effect bisoprolol ( low dose high dose ) surrogate marker heart failure Korea .</brief_summary>
	<brief_title>A Prospective , Open-labeled , Multi-centric Trial Subjects With Systolic Heart Failure Evaluate Bisoprolol Treatment Effects Surrogate Markers Heart Failure Korea</brief_title>
	<detailed_description>Subjects systolic congestive heart failure ( CHF ) enrol study proper evaluation NT-proBNP , global assessment CHF , 6-minute walk test improvement score New York Heart Association ( NYHA ) echocardiogram ( left ventricular chamber size ejection fraction [ LVEF ] ) . Each subject orally administer bisoprolol 6 month start 1.25 mg Week 0 titrate 10 mg 6 month period persistent stand systolic blood pressure ( SBP ) great ( &gt; ) 90 millimeter mercury ( mm Hg ) symptom hypotension current dose medication ( syncope , loss consciousness , dizziness standing ) . OBJECTIVES Primary objective : â€¢ To evaluate effect bisoprolol ( low dose high dose ) surrogate marker heart failure Korea Secondary objective : - To evaluate bisoprolol effect clinical improvement heart failure Korea : 1 . New York Heart Association ( NYHA ) , 2 . 6-minutes walk test 3 . Echocardiogram ( leave ventricular chamber size LVEF ) - Hospitalization due heart failure - To evaluate safety tolerability bisoprolol - Global assessment CHF</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<criteria>Subjects heart failure age 18 ( inclusive ) 80 ( exclusive ) Subjects NYHA Class IIIV dyspnea Subjects leave ventricular ejection fraction ( LVEF ) 40 percent echocardiogram Eligible subject meet criterion , capable participate study , provide write informed consent study participation receive clear explanation study objective nature A subject understand agree study content Subjects conduction defect 2nd degree atrioventricular block Subjects heart rate le ( &lt; ) 60 beat rest Subjects systolic blood pressure &lt; 100 mm Hg rest Subjects renal failure ( serum creatinine &gt; 2.0 milligram per deciliter [ mg/dL ] ) Subjects unrecovered pulmonary edema Subjects history myocardial infarction stroke within 3 month Subjects history coronary intervention coronary bypass within 6 month Subjects heart failure due mitral valve without valve replacement aortic valvular disease ( exclude moderate less severe mitral insufficiency secondary leave ventricular expansion ) Subjects history valve replacement within past 6 month Subjects history schedule heart transplantation Subjects reversible obstructive pulmonary disease Subjects case beta blocker contraindicate Any surgical internal disease may put subject high risk due study participation may interfere subject compliance study requirement completion study , base judgment Investigator A subject history noncompliance drug prescription willing comply protocol Subjects history treat untreated malignant tumor within past 5 year Pregnant lactating woman Subjects heart failure due acute myocarditis Subjects continuous ventricular tachycardia history syncope within 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Systolic heart failure</keyword>
	<keyword>Bisoprolol</keyword>
	<keyword>Concor</keyword>
	<keyword>Echocardiogram</keyword>
</DOC>